Get all your news in one place.
100's of premium titles.
One app.
Start reading
International Business Times UK
International Business Times UK
Robert Gorgonio

Moderna Shares Double Overnight Because a Made-to-Order mRNA Vaccine Actually Beats Skin Cancer

Moderna shares doubled after a personalised mRNA vaccine cut melanoma recurrence in a late-stage trial, sparking investor optimism and raising hopes for a new era in cancer treatment (Credit: By Fletcher - Own work, CC BY 4.0, via Wikimedia Commons)

Moderna shares surged in pre-market trading after the US biotech announced that its personalised mRNA cancer vaccine, intismeran, showed a statistically significant reduction in melanoma recurrence in a late-stage clinical trial.

The news, released on Wednesday, sent Moderna's stock soaring by more than 100 per cent in early trading as investors reacted to what some analysts described as a potentially significant development in personalised cancer treatment.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.